• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Turning Point Brands (TPB) Is Down 14.7% After Possible FDA Delays On Oral Nicotine Approvals

    Simply Wall St·04/03/2026 11:27:46
    Listen to the news
    • In late March 2026, reports suggested the FDA may delay authorization of certain oral nicotine products, including those Turning Point Brands has pending, as agency scientists weigh risks to new users and children.
    • This hesitancy introduces fresh regulatory uncertainty around modern oral pouches, a category that has become central to Turning Point Brands’ growth plans.
    • Next, we’ll examine how the potential for longer FDA approval timelines could reshape Turning Point Brands’ previously optimistic investment narrative.

    Outshine the giants: these 22 early-stage AI stocks could fund your retirement.

    Turning Point Brands Investment Narrative Recap

    To own Turning Point Brands today, you have to believe its pivot toward modern oral nicotine pouches can offset pressure in legacy tobacco and justify ongoing investment in sales, marketing, and distribution. The FDA’s hesitancy around oral nicotine authorizations directly affects the company’s most important short term catalyst, because slower approvals could delay new product launches in a category that already carries the biggest regulatory risk in the story.

    The most relevant recent update is management’s 2026 revenue guidance for Modern Oral gross sales of US$220 million to US$240 million, with net revenue of US$180 million to US$190 million. That outlook was set before the latest FDA reports, so investors now need to weigh whether any extended review timelines could affect how quickly Turning Point can scale those pouch sales and validate the bullish expectations around its modern oral platform.

    Yet behind the growth story, investors should be aware that any shift in how regulators treat flavored modern oral products could...

    Read the full narrative on Turning Point Brands (it's free!)

    Turning Point Brands’ narrative projects $890.0 million revenue and $163.0 million earnings by 2029. This requires 24.3% yearly revenue growth and about a $104.8 million earnings increase from $58.2 million today.

    Uncover how Turning Point Brands' forecasts yield a $132.50 fair value, a 84% upside to its current price.

    Exploring Other Perspectives

    TPB 1-Year Stock Price Chart
    TPB 1-Year Stock Price Chart

    Four fair value estimates from the Simply Wall St Community span roughly US$105 to US$159 per share, underscoring how far opinions can stretch. Readers should weigh those views against the heightened regulatory uncertainty now facing modern oral pouches and consider how different approval timelines might influence Turning Point Brands’ ability to sustain its recent momentum.

    Explore 4 other fair value estimates on Turning Point Brands - why the stock might be worth just $105.20!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Searching For A Fresh Perspective?

    Our top stock finds are flying under the radar-for now. Get in early:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.